NFKB1 and Nephropathy: Nicotinic agonist administration reduced IκBα degradation within the kidneys and significantly suppressed renal NFκB activation in vivo (Fig. 5), supporting the concept that targeting the NFκB pathway will protect against kidney damage associated with septic-AKI, as previously described [40], [41].